Over-the-Counter Alkali Agents to Raise Urine pH and Citrate Excretion: A Prospective Crossover Study in Healthy Adults.

Objective: To assess the effect of 2 over-the-counter alkalizing agents on 24 hour urinary parameters.

Materials And Methods: Ten healthy volunteers without a history of kidney stones were recruited to complete a baseline 24 hour urinalysis with a 4 day diet inventory. Participants then maintained the same diet on either LithoLyte (20 mEq 2 times per day) or KSPtabs (1 tablet 2 times per day) and submitted another 24 hour urinalysis.

Same Day Discharge is a Successful Approach for the Majority of Patients Undergoing Holmium Laser Enucleation of the Prostate.

Background: Limited research has focused on success with hospital discharge on the same day of surgery after holmium laser enucleation of the prostate (HoLEP).

Objective: To determine the success of same-day discharge in our HoLEP cohort and factors associated with this approach.

Design, Setting, And Participants: A retrospective review of our prospectively maintained HoLEP database demonstrated that 473 adult males underwent HoLEP from July 2018 to December 2019 at a tertiary referral center and high-volume HoLEP hospital.

Real-World Experience of Holmium Laser Enucleation of the Prostate with Patients on Anticoagulation Therapy.

Holmium laser enucleation of the prostate (HoLEP) is a highly effective procedure for benign prostatic hyperplasia that is size independent and has been recommended for patients necessitating antiplatelet (AP) and anticoagulant (AC) medications. Although HoLEP is feasible in AP/AC patients, there is a lack of published results on real-world outcomes of patients on AP/AC therapy undergoing HoLEP. We performed a retrospective review of our institutional HoLEP database of demographics, perioperative and postoperative data, and outcomes of patients on AP and AC therapy compared with none.

Initial Clinical Experience with Swiss LithoClast Trilogy During Percutaneous Nephrolithotomy.

Current available lithotrites have clinical stone clearance rates averaging 24 to 32 mm/minute. The objective of this study was to critically evaluate the initial experience with the Swiss LithoClast Trilogy lithotrite during percutaneous nephrolithotomy (PCNL). We prospectively enrolled patients with a minimum of 15 mm of stone in axial diameter at three locations (Indiana University, University of California Davis, and University of California San Diego) scheduled to undergo PCNL for nephrolithiasis over a 60-day trial period.